狠狠色丁香婷婷综合久小说久,国产亚洲精品第一综合另类 ,亚洲av无码精品色午夜飞机馆,国产无套码AⅤ在线观看

Keryx Biopharmaceuticals  
專注于收購，開發(fā)和商業(yè)化的醫(yī)學治療腎臟疾病的重要醫(yī)藥產(chǎn)品。

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of ZerenexTM for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Keryx Biopharmaceuticals is traded on the Nasdaq Stock Market under the symbol "KERX."